Evaluation of Therapeutic Equivalence

On 21July 2022 the FDA published the draft guidance on evaluation of therapeutic equivalence of generic drugs. Submit comments by 19 September 2022.

The draft guidance explains the criteria FDA uses to evaluate the therapeutic equivalence (TE) of drug products and what the TE codes indicate. The guidance explains how FDA evaluates drug products for, and determines TE for, multi-source drug products to be listed in the Approved Drug Products With Therapeutic Equivalence Evaluations publication (the Orange Book). The guidance provides background on the fundamentals of TE and utilizes a question and answer format to provide more information on the therapeutic equivalence evaluation of approved drug products and assignment of TE codes in the Orange Book.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /